Last updated on August 2019

This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses)

Brief description of study

The main objective of this trial is the safety and tolerability of 3 multiple rising oral doses of BI 685509 over 28 days in male and female patients with Diabetic Nephropathy (DN) as adjunctive to Angiotensin Converting Enzyme inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB). Another objective is the change in Urine Albumin Creatinine Ratio (UACR), an important diagnostic marker of nephropathy.

Clinical Study Identifier: NCT03165227

Find a site near you

Start Over

PMG Research of Wilmington, LLC

Wilmington, NC United States
  Connect »

Research by Design, LLC

Chicago, IL United States
  Connect »

York Clinical Research, LLC

Norfolk, VA United States
  Connect »

Scott Research, Inc.

Laurelton, NY United States
  Connect »

Nephrology Consultants, LLC

Huntsville, AL United States
  Connect »

South Florida Research Institute

Lauderdale Lakes, FL United States
  Connect »

Knoxville Kidney Center PLLC

Knoxville, TN United States
  Connect »